Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07831863) titled 'A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy' on Sept. 4.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
Condition:
Lung Squamous Cell Carcinoma
Intervention:
Drug: 7MW3711
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: October 2026
Target Sample Size: 600
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07831...